Work with Us

Disease Modifying Osteoarthritis Therapeutic

Disease Modifying Osteoarthritis Therapeutic Compounds

Quote: KT164958

The Challenge

Osteoarthritis (OA) is a debilitating condition affecting the joints. 8.75 million people in the UK have sought treatment for OA, which equates to one third of the population over 45 years.1 While the pathological sequence of events is not fully understood, cartilage matrix degradation is recognised as an early stage process. Preventing cartilage breakdown may help to stop or slow down disease progression.

The Solution

Newcastle University has identified a hit compound in clear IP space which inhibits the serine protease enzyme matriptase. Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis. Initial work in an in vivo mouse model of OA has shown protection from cartilage breakdown following administration of the hit compound by sub-cutaneous pump and intra-articular injection.

The Opportunity

We are looking for drug development organisations to partner with us through the next stage of lead validation

Intellectual Property Status

A preliminary patent has been filed in the UK describing the hit compounds and family of derivatives.

Title: Inhibitor Compounds
Application no: GB1621619.4
Filing Date: 19th December 2016
Applicant: University of Newcastle upon Tyne


Milner JM, Patel A, Davidson RK et al. (2010) Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis. Arthritis Rheum, 62(7):1955-66.


Dr Marie Labus, Enterprise Team, Research & Enterprise Services, Newcastle University, Faculty of Medical Sciences, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK